Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 3Active not recruiting 3Completed 2No longer available 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 3NSCLC 1

Interventions

pembrolizumab 29Carboplatin 27Specimen Handling 21durvalumab 20Pemetrexed 18Cisplatin 17Paclitaxel 16atezolizumab 15Nivolumab 15Magnetic Resonance Spectroscopy 15osimertinib 11Radiosurgery 11Radiotherapy 10Immunoglobulin G 10Etoposide 10Docetaxel 10Disulfides 10Radiation 9Taxes 8Gemcitabine 8Biopsy 8Blood Specimen Collection 7Standard of Care 6Practice Guidelines as Topic 6Ipilimumab 6Surveys and Questionnaires 5Platinum 5Bronchoscopy 5Bevacizumab 5Ramucirumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Lung Neoplasms × brigatinib × Clear all
NCT04223596 2026-02-04

CUBIK

Fundación GECP

Phase 2 Active not recruiting
33 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03707938 2025-11-03

Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
35 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04227028 2025-09-16

Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

City of Hope Medical Center

Phase 1 Active not recruiting
5 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡